MCID: MLG079
MIFTS: 50

Malignant Pleural Mesothelioma malady

Category: Cancer diseases

Aliases & Classifications for Malignant Pleural Mesothelioma

About this section

Aliases & Descriptions for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 11 13 68
Malignant Mesothelioma of Pleura 11
 
Pleural Malignant Mesothelioma 50

Classifications:



External Ids:

Disease Ontology11 DOID:7474
ICD1030 C45.0
NCIt45 C7376

Summaries for Malignant Pleural Mesothelioma

About this section
Disease Ontology:11 A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary: Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to renal cell carcinoma and lung cancer, and has symptoms including chest pain, dyspnea and fatigue. An important gene associated with Malignant Pleural Mesothelioma is SPP1 (Secreted Phosphoprotein 1), and among its related pathways are FGF signaling pathway and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. Affiliated tissues include lung, t cells and endothelial, and related mouse phenotypes are neoplasm and muscle.

Related Diseases for Malignant Pleural Mesothelioma

About this section

Diseases in the Benign Pleural Mesothelioma family:

malignant pleural mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 111)
idRelated DiseaseScoreTop Affiliating Genes
1renal cell carcinoma29.1BIRC5, EGFR, MET, MUC1, NKX2-1, WT1
2lung cancer28.7BIRC5, CDH2, CDKN2A, EGFR, MET, NKX2-1
3mesothelioma, somatic28.1CALB2, CDH2, CDKN2A, LINC01194, MET, MSLN
4nipple neoplasm10.7CALB2, WT1
5adenosarcoma10.6CALB2, WT1
6femoral cancer10.6CDKN2A, WT1
7extragonadal seminoma10.6CALB2, CDKN2A
8pseudounicornuate uterus10.6EGFR, NKX2-1
9pseudosarcomatous fibromatosis10.6CALB2, MUC1
10glottis verrucous carcinoma10.6EGFR, MUC1
11distal monosomy 7q3610.5BIRC5, EGFR, MUC1
12ovarian cyst10.5CALB2, MUC1
13adenosquamous pancreas carcinoma10.5CDKN2A, EGFR
14central centrifugal cicatricial alopecia10.5CDKN2A, EGFR, MUC1
15endometriosis of pelvic peritoneum10.5MUC1, WT1
16psammomatous meningioma10.4CDKN2A, WT1
17angiokeratoma circumscriptum10.4CDKN2A, EGFR, WT1
18orbital varix10.4EGFR, PDPN
19pulmonary artery leiomyosarcoma10.4CALB2, THBD
20sebaceous adenoma10.4THBD, WT1
21nasal cavity adenocarcinoma10.4EGFR, MUC1, SPP1
22richter's syndrome10.4CDKN2A, EGFR, MUC1
23epididymis cancer10.4BIRC5, WT1, XIAP
24estrogen-receptor negative breast cancer10.4CDKN2A, EGFR, MUC1
25dysgraphia10.4EGFR, MUC1, NKX2-1
26sphenoidal sinus cancer10.4CALB2, NKX2-1, THBD
27localized pulmonary fibrosis10.4CALB2, NKX2-1, THBD
28anus disease10.4CDKN2A, EGFR, MUC1
29tricuspid valve insufficiency10.4CALB2, MUC1
30external ear disease10.3MUC1, NKX2-1
31persian gulf syndrome10.3CALB2, THBD, WT1
32autoimmune hemolytic anemia10.3CDKN2A, EGFR
33desmoplastic infantile astrocytoma10.3BIRC5, CDH2, CDKN2A
34herpes simplex10.3CDKN2A, EGFR, MET
35pancreatic somatostatinoma10.3CDKN2A, EGFR, MSLN, MUC1
36trachea sarcoma10.3CDKN2A, EGFR, MSLN, MUC1
37tonsil cancer10.3BIRC5, EGFR, MET
38paroxysmal nocturnal hemoglobinuria10.3CDKN2A, EGFR, MSLN, MUC1
39hodgkin's granuloma10.3CDH2, CDKN2A, EGFR
40follicular adenoma10.3CALB2, MUC1, THBD
41large cell keratinizing variant squamous cell breast carcinoma10.3NKX2-1, THBD, WT1
42dental caries10.3EGFR, MSLN, MUC1, WT1
43ovarian wilms' cancer10.3EGFR, MSLN, MUC1, WT1
44antidepressant or antipsychotic toxicity or dose selection10.3BIRC5, CALB2, PDPN
45submucosal invasive colon adenocarcinoma10.3CDKN2A, EGFR, MUC1, NKX2-1
46ductal carcinoma in situ10.3CDKN2A, EGFR, PDPN
47serous cystadenocarcinoma10.3CDH2, MUC1, NKX2-1
48brown-vialetto-van laere syndrome10.3CDKN2A, EGFR, MUC1, NKX2-1
49megarbane jalkh syndrome10.2MUC1, THBD, WT1
50mixed germ cell-sex cord neoplasm10.2BIRC5, CDKN2A, EGFR, MUC1

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to malignant pleural mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

About this section

UMLS symptoms related to Malignant Pleural Mesothelioma:


chest pain, dyspnea, fatigue, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

41 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.3BAP1, CDKN2A, EGFR, MET, NKX2-1, SPP1
2MP:00053698.6BAP1, CDH2, CDKN2A, EGFR, MET, PDPN
3MP:00028738.5BIRC5, CALB2, EGFR, MET, MSLN, NKX2-1
4MP:00053978.4BAP1, BIRC5, CDKN2A, EGFR, PDPN, PPP1R15A
5MP:00053808.3BAP1, BIRC5, CDH2, CDKN2A, EGFR, MET
6MP:00053858.3BAP1, CDH2, CDKN2A, EGFR, MET, NKX2-1
7MP:00053888.2CDKN2A, EGFR, MET, NKX2-1, PDPN, SPP1
8MP:00053878.0BAP1, BIRC5, CDKN2A, EGFR, MET, PDPN
9MP:00053768.0BAP1, BIRC5, CDH2, CDKN2A, EGFR, MET
10MP:00053787.8BAP1, CDH2, CDKN2A, EGFR, MET, NKX2-1
11MP:00053847.3BAP1, BIRC5, CDH2, CDKN2A, EGFR, MET
12MP:00107686.8BAP1, BIRC5, CDH2, CDKN2A, EGFR, MET

Drugs & Therapeutics for Malignant Pleural Mesothelioma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Alimta16 44 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
FDA Label: Alimta
Disease/s that Drug Treats:Mesothelioma
Indications and Usage:16 ALIMTA® is a folate analog metabolic inhibitor indicated for: Locally Advanced or Metastatic Nonsquamous Non-Small CellLung Cancer: Initial treatment in combination with cisplatin. (1.1) Maintenance treatment of patients whose disease has notprogressed after four cycles of platinum-based first-linechemotherapy. (1.2) After prior chemotherapy as a single-agent. (1.3) Mesothelioma: in combination with cisplatin. (1.4)Limitations of Use: ALIMTA is not indicated for the treatment of patients withsquamous cell non-small cell lung cancer. (1.5)
DrugBank Targets:14 1. Thymidylate synthase;2. Bifunctional purine biosynthesis protein PURH;3. Dihydrofolate reductase;4. Trifunctional purine biosynthetic protein adenosine-3
Mechanism of Action:16 
Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase
Action: antagonist/ inhibitor
FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependentmetabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibitsthymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate bindingprotein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzymefolylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to alesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-liferesulting in prolonged drug action in malignant cells.

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 187)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Pemetrexedapproved, investigationalPhase 3, Phase 2, Phase 1617150399-23-8, 137281-23-3446556, 60843
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
 
HSDB 7316
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY-231514
LY231514
LY231514 disodium
LYA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NCGC00167517-01
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed Disodium
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
nchembio.108-comp6
2
CisplatinapprovedPhase 3, Phase 2, Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
3
Vinorelbineapproved, investigationalPhase 3, Phase 2, Phase 137171486-22-160780, 44424639
Synonyms:
5'-Noranhydrovinblastine
71486-22-1
AC1L1KVK
AC1L1TWQ
AC1L75Q4
ANX-530
Ambap71486-22-1
BIDD:PXR0186
C45H54N4O8
CHEBI:480999
CHEMBL607994
CID355119
CID5311497
CID5672
CID60780
CID6426842
D08680
DB00361
Eunades
Exelbine
HMS2090E13
HSDB 7665
I06-0084
I06-0085
KW 2307
KW 2307 base
KW-2307
 
LS-97533
MolPort-006-822-661
MolPort-006-823-869
NCGC00165966-02
NVB
Navelbine
Navelbine (TN)
Navelbine Base
Navelbine base
Nor-5'-anhydrovinblastine
SDP-012
UNII-Q6C979R91Y
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
Vinorelbine
Vinorelbine (INN)
Vinorelbine Bitartrate
Vinorelbine Ditartarate
Vinorelbine Ditartrate
Vinorelbine Tartrate
Vinorelbine [INN:BAN]
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
vinorelbine
4
GemcitabineapprovedPhase 3, Phase 2, Phase 1197495058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
5
Dexamethasoneapproved, investigational, vet_approvedPhase 3, Phase 2, Phase 1208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
6
VinblastineapprovedPhase 3, Phase 2, Phase 1413865-21-413342, 241903
Synonyms:
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2alpha,2'BETA,3beta,4alpha,5beta)-vincaleukoblastine
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC-20335
AC1L21JC
AC1L68D2
AC1MXZJ2
BIDD:PXR0201
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
Bio-0111
C07201
C46H58N4O9
CCRIS 9002
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EINECS 212-734-0
HMS2090K05
HSDB 3263
KBio3_003033
LS-1859
LS-187263
 
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NCI-C04842
NCI60_004200
NChemBio.2007.10-comp22
NDC 0002-1452-01
NSC 47842
Neuro_000020
Nincaluicolflastine
Rozevin
SPBio_000680
STOCK1N-38480
Spectrum2_000890
Spectrum3_001994
UNII-5V9KLZ54CY
VLB
VR-8
Velban
Velbe
Vinblastin
Vinblastina
Vinblastina (TN)
Vinblastina [DCIT]
Vinblastina [Dcit]
Vinblastine
Vinblastine (INN)
Vinblastine Sulfate
Vinblastine [INN:BAN]
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
nchembio873-comp22
vinblastine
7
CarboplatinapprovedPhase 3, Phase 2, Phase 1198041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
8
HydroxocobalaminapprovedPhase 2, Phase 324813422-51-011953898, 5460373, 44475014
Synonyms:
13422-51-0
22465-48-1
78091-12-0
8017-22-9
Acti-B12
AlphaRedisol
AlphaRedisol (TN)
Axion
Axlon
Benzimidazolyl ribofuranosyl phosphate deriv.
C08230
C62H85CoN13O15P
CHEBI:27786
CHEMBL1200742
CHEMBL235822
CID11622291
CID11953898
CID5460373
CID6433575
CID6474319
Ciplamin H
Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide
Cobalex
Cobalin H
Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-a-D-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosylbenzimidazole inner salt
Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'- ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole
Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole
Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole
Codroxomin
Cyanokit
Cyanokit (TN)
D01027
DB00200
Depogamma
Docclan
Docelan
Docelvita
Docevita
Droxomin
Ducobee Hy
Ducobee-Hy
Duradoce
Duralta-12
EINECS 236-533-2
HSDB 3342
HYDROXOCOBALAMIN
Hidroxocobalamina
Hidroxocobalamina [INN-Spanish]
Hydro Cobex
 
Hydrobamine
Hydrocobalamin
Hydrogrisevit
Hydrovit
Hydroxocobalamin
Hydroxocobalamin (JAN/USP/INN)
Hydroxocobalamin Vitamin B12
Hydroxocobalamin [USAN:INN:BAN:JAN]
Hydroxocobalamin acetate
Hydroxocobalamin anhydrous
Hydroxocobalamin monohydrochloride
Hydroxocobalamin(alkaline soln.), OH- replaces CN- in Cyanocobalamin)
Hydroxocobalaminacetat
Hydroxocobalamine
Hydroxocobalamine [INN-French]
Hydroxocobalaminum
Hydroxocobalaminum [INN-Latin]
Hydroxocobalaminum anhydrous
Hydroxocobemine
Hydroxomin
Hydroxy Cobal
Hydroxy vitamin B12
Hydroxycob(lll)alamin
Hydroxycobalamin
Hydroxycobalamine
Hyxobamine
Idrogrisevit
Idrossocobalamina
Idrossocobalamina [DCIT]
LS-54607
Lyovit-H
Neo-Betalin 12
Neo-cytamen
Neo-macrabin
Neo-rojamin
OH-Cbl
OH-Duphar
Ohb12
Oxobemin
Oxolamine (arcum)
Primabalt RP
Redisol-H
S1668_Selleck
Sytobex-H
UNII-Q40X8H422O
Vibeden
Vitadurin
Vitamin B(sub 12a)
Vitamin B-12b
Vitamin B12a
Vitamin B12b
a-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
alpha Cobione
alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
vitamin B-12b
9
Doxorubicinapproved, investigationalPhase 3, Phase 2171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
10
Bevacizumabapproved, investigationalPhase 2, Phase 3, Phase 11968216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
11
Vorinostatapproved, investigationalPhase 3, Phase 1, Phase 2242149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
12
Raltitrexedapproved, investigationalPhase 3, Phase 1, Phase 230112887-68-0104758
Synonyms:
(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid
(S)-2-[(1-{5-[Methyl-(2-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-amino]-thiophen-2-yl}-methanoyl)-amino]-pentanedioic acid
112887-68-0
1i00
2kce
2tsr
AC-19671
AC1L2XFZ
Arkomedika brand of raltitrexed
AstraZeneca brand of raltitrexed
Bio-0142
C068874
C11372
C21H22N4O6S
CHEBI:41742
CHEBI:474007
CHEMBL225071
CID104758
CPD000469217
D 1694
D-1694
D01064
D16
D1694
DB00293
HMS2052I03
 
ICI D1694
ICI-D-1694
ICI-D1694
KS-5069
LS-71840
MLS001424225
N-(5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thenoyl)-L-glutamic acid
N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid
NCI60_013008
NSC-639186
NSC639186
Raltitrexed
Raltitrexed (JAN/USAN/INN)
S1192_Selleck
SA-Detection Disk Kit
SAM001246796
SMR000469217
Tomudex
Tomudex (TN)
Tomudex, TDX, ZD 1694, Raltitrexed
ZD 1694
ZD-16
ZD-1694
ZD1694
ZN-D1694
Zeneca brand of raltitrexed
raltitrexed
13
Vincristineapproved, investigationalPhase 39042068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
14
NintedanibapprovedPhase 3, Phase 2113656247-17-556843413
Synonyms:
BIBF 1120
BIBF1120
 
Vargatef
methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate
nintedanib
15
nivolumabapprovedPhase 3, Phase 2326946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
16
PembrolizumabapprovedPhase 3, Phase 2, Phase 14211374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
17
Cyanocobalaminapproved, nutraceuticalPhase 2, Phase 324968-19-944176380
Synonyms:
Anacobin
Bedoz
Berocca PN
Berubigen
Betalin 12
Betalin 12 Crystalline
Betaline-12
Betolvex
Bevidox
Bevidox concentrate
Biocobalamine
Byladoce
Cabadon m
Cernevit-12
Cobadoce forte
Cobalin
Cobavite
Cobex
Cobolin-M
Copharvit 5000
Covit
Crystamin
Crystamine
Crysti-12
Crystimin
Crystwel
Cyano-B12
Cyanobalamin concentrate
Cyanocob(III)alamin
Cyanocobalamin (JP15/USP)
Cyanocobalamin Co 57 Schilling Test Kit
Cyanocobalamine
Cyanocobalmin
Cyanoject
Cycobemin
Cycolamin
Cykobemin
Cykobeminet
Cyomin
Cyredin
Cytacon
Cytamen
Cytobion
Depinar
Dicopac
Dicopac Kit
Dimethylbenzimidazoylcobamide
Distivit
Docemine
Docibin
Docivit
Dodecabee
Dodecavite
Dodex
Duodecibin
Embiol
Emociclina
Eritrone
Erycytol
 
Erythrotin
Euhaemon
Extrinsic factor
Factor II
Fermin
Fresmin
Hemomin
Hepagon
Hepavis
Hepcovite
Hylugel plus
Infuvite Pediatric
Lactobacillus lactis dorner factor
M.V.I. Pediatric
Macrabin
Megabion
Megalovel
Milbedoce
Millevit
Nagravon
Nascobal
Nascobal (TN)
Neuroforte-R
Normocytin
Novidroxin
Pernaemon
Pernaevit
Pernipuron
Plecyamin
Poyamin
Primabalt
Rebramin
Redamina
Redisol
Rhodacryst
Rubesol
Rubivite
Rubramin
Rubramin PC
Rubratope-57 Kit
Rubratope-60 Kit
Rubripca
Rubrocitol
Ruvite
Shovite
Sytobex
Vi-Twel
Vibal
Vibalt
Vibisone
Virubra
Vita-rubra
Vitabee 12
Vitamin B12
Vitamin B12 Preparation
Vitamin B12 complex
Vitaped
Vitarubin
Vitral
vitamine b12
18
Folic Acidapproved, nutraceutical, vet_approvedPhase 3, Phase 2, Phase 1427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
19
DoxilApproved June 1999Phase 3, Phase 2171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
20RanpirnaseinvestigationalPhase 33196488-72-9
21Vinca AlkaloidsPhase 3, Phase 225
22Dexamethasone 21-phosphatePhase 3, Phase 2, Phase 12084
23Anti-Bacterial AgentsPhase 3, Phase 2, Phase 110884
24AntiemeticsPhase 3, Phase 2, Phase 13888
25BB 1101Phase 3, Phase 2, Phase 12084
26Dexamethasone acetatePhase 3, Phase 2, Phase 120841177-87-3
27Trace ElementsPhase 3, Phase 25802
28Antiviral AgentsPhase 3, Phase 2, Phase 19732
29VitaminsPhase 2, Phase 35095
30Immunosuppressive AgentsPhase 3, Phase 2, Phase 112770
31Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 122776
32Gastrointestinal AgentsPhase 3, Phase 2, Phase 18109
33MicronutrientsPhase 3, Phase 25802
34Anti-Infective AgentsPhase 3, Phase 2, Phase 121402
35Autonomic AgentsPhase 3, Phase 2, Phase 19774
36Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 15420
37AntimetabolitesPhase 3, Phase 2, Phase 111774
38Vitamin B ComplexPhase 3, Phase 2, Phase 14229
39Nucleic Acid Synthesis InhibitorsPhase 3, Phase 2, Phase 14855
40Folic Acid AntagonistsPhase 3, Phase 2, Phase 12200
41Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17171
42Antimitotic AgentsPhase 3, Phase 2, Phase 15498
43Vitamin B 12Phase 2, Phase 3249
44Antibiotics, AntitubercularPhase 3, Phase 2, Phase 16972
45Topoisomerase InhibitorsPhase 3, Phase 24945
46AnalgesicsPhase 3, Phase 2, Phase 111287
47Alkylating AgentsPhase 3, Phase 2, Phase 14694
48Histone Deacetylase InhibitorsPhase 3, Phase 2, Phase 1566
49ImmunoglobulinsPhase 3, Phase 2, Phase 16045
50MitomycinsPhase 3233

Interventional clinical trials:

(show top 50)    (show all 190)
idNameStatusNCT IDPhase
1ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy RegimenUnknown statusNCT00003034Phase 3
2Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)CompletedNCT00128102Phase 3
3Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00075699Phase 3
4Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by SurgeryCompletedNCT00005636Phase 3
5Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the PleuraCompletedNCT00004920Phase 3
6A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of MesotheliomaCompletedNCT00190762Phase 3
7Mesothelioma Avastin Plus Pemetrexed-cisplatin StudyCompletedNCT00651456Phase 2, Phase 3
8Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2CompletedNCT01836575Phase 3
9Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant MesotheliomaCompletedNCT00821860Phase 3
10Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and CisplatinRecruitingNCT02709512Phase 2, Phase 3
11PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural MesotheliomaRecruitingNCT01604005Phase 3
12Nintedanib (BIBF 1120) in MesotheliomaRecruitingNCT01907100Phase 3
13Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsRecruitingNCT02899299Phase 3
14NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With PemetrexedActive, not recruitingNCT01098266Phase 3
15PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural MesotheliomaNot yet recruitingNCT02991482Phase 3
16A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural MesotheliomaUnknown statusNCT01279967Phase 2
17Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural MesotheliomaUnknown statusNCT00886028Phase 2
18Trimodal Lung-Sparing Treatment of Pleural MesotheliomaUnknown statusNCT00859495Phase 2
19Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural MesotheliomaUnknown statusNCT00354393Phase 2
20A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural MesotheliomaUnknown statusNCT01569919Phase 2
21A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.Unknown statusNCT00996567Phase 2
22S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By SurgeryUnknown statusNCT00770120Phase 2
23Vinorelbine in MesotheliomaUnknown statusNCT02139904Phase 2
24Axitinib in Malignant MesotheliomaUnknown statusNCT01211275Phase 1, Phase 2
25Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal MesotheliomaUnknown statusNCT00996385Phase 2
26Eloxatin® Plus Gemcitabine Chemotherapy for MesotheliomaUnknown statusNCT00859469Phase 2
27ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.Approved for marketingNCT00040625Phase 2
28Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural MesotheliomaCompletedNCT00386815Phase 2
29Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural MesotheliomaCompletedNCT00484276Phase 2
30Study of Carboplatin and Vinorelbine in Malignant Pleural MesotheliomaCompletedNCT00272558Phase 2
31Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict SensitivityCompletedNCT01024946Phase 2
32Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma TreatmentCompletedNCT01243632Phase 2
33A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT01486368Phase 2
34Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)CompletedNCT00700336Phase 1, Phase 2
35Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural MesotheliomaCompletedNCT01112293Phase 2
36Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural MesotheliomaCompletedNCT00251550Phase 1, Phase 2
37Pazopanib in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00459862Phase 2
38Bortezomib in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00513877Phase 2
39S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00243074Phase 2
40Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00227630Phase 2
41Sunitinib in Treating Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT00392444Phase 2
42An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural MesotheliomaCompletedNCT00738582Phase 2
43Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural MesotheliomaCompletedNCT00407459Phase 2
44Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural MesotheliomaCompletedNCT00004033Phase 2
45Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT00101283Phase 2
46Isolated Thoracic Perfusion (ITP-F) for MPMCompletedNCT02467426Phase 2
47Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium ThiosulfateCompletedNCT00165516Phase 2
48Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural MesotheliomaCompletedNCT00087698Phase 2
49Surgery and Photodynamic Therapy in Treating Patients With Malignant MesotheliomaCompletedNCT00054002Phase 2
50Erlotinib in Treating Patients With Malignant Mesothelioma of the LungCompletedNCT00039182Phase 2

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

About this section

Anatomical Context for Malignant Pleural Mesothelioma

About this section

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

36
Lung, T cells, Endothelial, Testes, Liver, Thymus, Bone

Publications for Malignant Pleural Mesothelioma

About this section

Articles related to Malignant Pleural Mesothelioma:

(show top 50)    (show all 780)
idTitleAuthorsYear
1
Asbestos fibres detected by scanning electron microscopy in the gallbladder of patients with malignant pleural mesothelioma (MPM). (28066892)
2017
2
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. (28027772)
2017
3
Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma. (27881012)
2017
4
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence. (27979596)
2017
5
Open access phone triage for veterans with suspected malignant pleural mesothelioma. (27979465)
2017
6
Prognostic value of pretreatment volume-based quantitative (18)F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. (28027744)
2017
7
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : AA propensity score matching of the SEER database. (28044200)
2017
8
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment. (28051015)
2017
9
KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. (26780987)
2016
10
207O: Extended pleurectomy decortication for malignant pleural mesothelioma in the elderly - the need for an inclusive yet selective approach. (27198343)
2016
11
Manumycin A induces apoptosis in malignant pleural mesothelioma through regulation of Sp1 and activation of the mitochondria-related apoptotic pathway. (27176604)
2016
12
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. (27903668)
2016
13
Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma. (27197170)
2016
14
Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review. (27057918)
2016
15
Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent. (26773069)
2016
16
Pain in Malignant Pleural Mesothelioma: A Prospective Characterization Study. (27117437)
2016
17
Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature. (27993826)
2016
18
The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma. (26440572)
2016
19
Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma. (27621868)
2016
20
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. (27094927)
2016
21
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. (27584578)
2016
22
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests. (27614970)
2016
23
209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma. (27198344)
2016
24
Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma. (27068290)
2016
25
Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. (27009350)
2016
26
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma. (26762744)
2016
27
Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma. (27646775)
2016
28
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). (27133741)
2016
29
Perspective on malignant pleural mesothelioma diagnosis and treatment. (27127773)
2016
30
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. (26824986)
2016
31
Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Novel Mini-Invasive Technique. (27926627)
2016
32
210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia. (27198346)
2016
33
Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma. (27091358)
2016
34
FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma. (27853379)
2016
35
Erratum: Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea. (27587973)
2016
36
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis. (27198347)
2016
37
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? (27597274)
2016
38
Calpeptin Prevents Malignant Pleural Mesothelioma Cell Proliferation via the Angiopoietin1/Tie2 System. (27509983)
2016
39
A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma. (27074478)
2016
40
Recurrent hydropneumothorax: An unusual presentation for malignant pleural mesothelioma. (27489758)
2016
41
Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor. (27660729)
2016
42
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. (27596916)
2016
43
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. (27623107)
2016
44
Intensity-modulated radiotherapy for relapsed malignant pleural mesothelioma. (27651129)
2016
45
Alveolar-filling growth pattern of sarcomatoid malignant pleural mesothelioma. (27516891)
2016
46
Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions. (27663394)
2016
47
Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma. (27565933)
2016
48
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. (27512118)
2016
49
Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma. (27987139)
2016
50
208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial. (27198358)
2016

Variations for Malignant Pleural Mesothelioma

About this section

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

6 (show all 35)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
113406112300000LossPleural malignant mesothelioma
22183911620000028000000LossPleural malignant mesothelioma
33395115070000061300000AmplificationPleural malignant mesothelioma
435953169700000116100000LossPleural malignant mesothelioma
535955169700000116100000LossCLCA1Pleural malignant mesothelioma
635957169700000116100000LossCLCA2Pleural malignant mesothelioma
735959169700000116100000LossCLCA3Pleural malignant mesothelioma
835961169700000116100000LossCLCA4Pleural malignant mesothelioma
935963169700000116100000LossCOL11A1Pleural malignant mesothelioma
1035965169700000116100000LossTGFBR3Pleural malignant mesothelioma
1135967169700000120600000LossPleural malignant mesothelioma
1237057184900000107200000LossPleural malignant mesothelioma
1369953125660000058100000GainPleural malignant mesothelioma
1475173131790000045800000LossBRCA2Pleural malignant mesothelioma
15857391450900000107349540LossCCNKPleural malignant mesothelioma
16857411450900000107349540LossCDKN3Pleural malignant mesothelioma
17113646174490000081195210GainERN1Pleural malignant mesothelioma
18113648174490000081195210GainMAP3K3Pleural malignant mesothelioma
19113650174490000081195210GainPRKCAPleural malignant mesothelioma
20113652174490000081195210GainSMARCD2Pleural malignant mesothelioma
2117542333940000063700000LossCACNA2D3Pleural malignant mesothelioma
2217542533940000063700000LossCTNNB1Pleural malignant mesothelioma
2317542733940000063700000LossMLH1Pleural malignant mesothelioma
2417577234410000044200000LossPleural malignant mesothelioma
25187515450400000191154276LossPleural malignant mesothelioma
261917065148400000GainPleural malignant mesothelioma
272047306114600000118300000LossHDAC2Pleural malignant mesothelioma
282047326114600000118300000LossMARCKSPleural malignant mesothelioma
29217076714500000GainPleural malignant mesothelioma
302348728139900000146364022GainPleural malignant mesothelioma
3125002791990000025600000LossC9orf14Pleural malignant mesothelioma
3225003091990000025600000LossCDKN2APleural malignant mesothelioma
3325003291990000025600000LossCDKN2BPleural malignant mesothelioma
3425007091990000033200000LossPleural malignant mesothelioma
3525188593320000036300000GainPleural malignant mesothelioma

Expression for genes affiliated with Malignant Pleural Mesothelioma

About this section
Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for genes affiliated with Malignant Pleural Mesothelioma

About this section

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.8CDH2, MET, SPP1
29.7BAP1, CDH2, SPP1
39.7CDH2, MSLN, MUC1
49.0CDH2, EGFR, TXN
59.0BIRC5, CDKN2A, EGFR, MET, XIAP

GO Terms for genes affiliated with Malignant Pleural Mesothelioma

About this section

Biological processes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1inhibition of cysteine-type endopeptidase activity involved in apoptotic processGO:199000110.6BIRC5, XIAP
2cerebral cortex cell migrationGO:002179510.4EGFR, NKX2-1
3positive regulation of bone resorptionGO:00457809.9EGFR, SPP1
4lung developmentGO:00303249.7EGFR, NKX2-1, PDPN
5cell proliferationGO:00082838.9EGFR, MET, PDPN, TXN, TYMS

Molecular functions related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein phosphatase bindingGO:00199039.2CDH2, EGFR, MET, PPP1R15A

Sources for Malignant Pleural Mesothelioma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet